Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer-Reference-Cited by-同舟云学术

Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer

Published:2015-11-07 Issue:6 Volume:76 Page:1191-1198
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kobayashi Shogo,Tomokuni Akira,Gotoh Kunihito,Takahashi Hidenori,Akita Hirofumi,Marubashi Shigeru,Yamada Terumasa,Teshima Teruki,Nishiyama Kinji,Yano Masahiko,Ohigashi Hiroaki,Ishikawa Osamu,Sakon Masato

Funder

Grant-in-Aid for Scientific Research

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2908-3.pdf

Reference27 articles.

1. Yamanaka K, Hatano E, Kanai M, Tanaka S, Yamamoto K, Narita M, Nagata H, Ishii T, Machimoto T, Taura K, Uemoto S (2014) A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. Int J Clin Oncol 19:485–489

2. Kobayashi S, Nagano H, Marubashi S, Wada H, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M (2011) Treatment of borderline cases for curative resection of biliary tract cancer. J Surg Oncol 104:499–503

3. Miyakawa S, Ishihara S, Horiguchi A, Takada T, Miyazaki M, Nagakawa T (2009) Biliary tract cancer treatment: 5584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg 16:1–7